Spots Global Cancer Trial Database for advanced malignancies
Every month we try and update this database with for advanced malignancies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State | NCT01930006 | Advanced Malign... | MGCD265 | 18 Years - 55 Years | Mirati Therapeutics Inc. | |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| Phase I Clinical Study of BR105 Injection | NCT05351697 | Advanced Malign... | BR105 injection | 18 Years - 75 Years | BioRay Pharmaceutical Co., Ltd. | |
| A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas | NCT03763149 | Advanced Malign... | IBI188 | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | NCT02740270 | Solid Tumors Lymphomas | GWN323 PDR001 | 18 Years - | Novartis | |
| Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers | NCT01079286 | Renal Cell Canc... Cancer | Nelfinavir and ... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. | NCT00676299 | Protein Kinase ... Antineoplastic ... Clinical Trial,... Maximum Tolerat... Pharmacokinetic... Advanced Malign... Solid Malignanc... | JNJ-26483327 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study of NX-1607 in Adults With Advanced Malignancies | NCT05107674 | Ovarian Cancer,... Gastric Cancer GastroEsophagea... Head and Neck S... Metastatic or U... Non-small Cell ... Metastatic Cast... Malignant Pleur... Triple Negative... Metastatic Urot... Cervical Cancer Diffuse Large B... Richter Transfo... Microsatellite ... | NX-1607 Paclitaxel | 18 Years - | Nurix Therapeutics, Inc. | |
| A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors | NCT02697591 | Advanced Malign... Metastatic Canc... | INCAGN01876 | 18 Years - | Incyte Corporation | |
| A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas | NCT01051635 | Neoplasms Lymphoma | LMP400 LMP776 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies | NCT02013804 | Advanced Malign... | MEDI0680 (AMP-5... | 18 Years - 99 Years | MedImmune LLC | |
| Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study | NCT02520245 | Advanced Malign... | REGN2810 | 18 Years - | Regeneron Pharmaceuticals | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | NCT06202261 | Metastatic Brea... Recurrent Breas... Advanced Malign... | TQB2930 for inj... Paclitaxel for ... TQB3616 capsule Fulvestrant inj... Capecitabine ta... Vinorelbine tar... Eribulin mesyla... gemcitabine hyd... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors | NCT04085185 | Advanced Malign... | IBI110 IBI110 IBI110+ Sintili... IBI110+ Sintili... | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors | NCT03995472 | Advanced Malign... | SHR-1501 SHR-1316 | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors | NCT03995472 | Advanced Malign... | SHR-1501 SHR-1316 | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies. | NCT00426140 | Advanced Malign... Solid Tumors | Patupilone | 18 Years - | Novartis | |
| PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor | NCT02873390 | PD-1 Antibody CAR-T Cells Advanced Malign... | HerinCAR-PD1 ce... | 18 Years - 65 Years | Ningbo Cancer Hospital | |
| Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies | NCT04181788 | Advanced Malign... Non-small-cell ... | PF-06801591 | 18 Years - | Pfizer | |
| A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors | NCT04353830 | Advanced Malign... | IBI939 IBI939+ Sintili... IBI939+ Sintili... | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Japanese BAY1000394 Monotherapy Phase I Study | NCT02047890 | Neoplasms | BAY1000394 (2.5... BAY1000394 (5mg... | 20 Years - | Bayer | |
| Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer | NCT02862561 | Precision Cell ... Chemotherapy Advanced Malign... | Chemotherapy Precision Cells | 18 Years - 65 Years | Shanghai International Medical Center | |
| Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies | NCT05577182 | Advanced Malign... | INCA32459-101 | 18 Years - | Incyte Corporation | |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | NCT06401356 | Hematologic Mal... Solid Tumor Advanced Malign... | Pelabresib | 18 Years - | Constellation Pharmaceuticals | |
| Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors | NCT04328831 | Advanced Malign... | IBI322 | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Sirolimus and Cetuximab in Advanced Malignancies | NCT00940381 | Advanced Cancer | Sirolimus Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. | NCT04831944 | Advanced Malign... | parsaclisib | 18 Years - 80 Years | Incyte Corporation | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses | NCT05674825 | Cancer | Targeted agent Standard of car... | 18 Years - | Medical College of Wisconsin | |
| A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies | NCT00741403 | Advanced Cancer Metastatic Canc... Lymphoma Solid Tumors Advanced Malign... | CPI-613 | 18 Years - | Cornerstone Pharmaceuticals | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers | NCT01079286 | Renal Cell Canc... Cancer | Nelfinavir and ... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | NCT05059522 | Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors | Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600 | 18 Years - | Pfizer | |
| A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors | NCT02697591 | Advanced Malign... Metastatic Canc... | INCAGN01876 | 18 Years - | Incyte Corporation | |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | NCT04164199 | Advanced Malign... | Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007 | 18 Years - | BeiGene | |
| Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas | NCT01794104 | Neoplasm Lymphoma | LMP400 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer | NCT01938638 | Neoplasms | BAY1143572 | 21 Years - | Bayer | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies | NCT00215605 | Lymphoma Cancer Thyroid Carcino... | XL184 | 18 Years - | Exelixis | |
| A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | NCT02923349 | Advanced Malign... Metastatic Canc... | INCAGN01949 | 18 Years - | Incyte Corporation | |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | NCT04537715 | All Malignancie... Advanced Malign... Hematologic Mal... Solid Tumor Follicular Lymp... Non-Hodgkin Lym... Diffuse Large B... Epithelioid Sar... Synovial Sarcom... Renal Medullary... Mesothelioma Rhabdoid Tumor | Tazemetostat Itraconazole Tazemetostat Rifampin | 18 Years - | Ipsen | |
| Japanese BAY1000394 Monotherapy Phase I Study | NCT02047890 | Neoplasms | BAY1000394 (2.5... BAY1000394 (5mg... | 20 Years - | Bayer | |
| Clinical Study of 1A46 Drug Substance | NCT05987605 | Advanced Malign... | 1A46 Drug Subst... | 18 Years - | BioRay Pharmaceutical Co., Ltd. | |
| The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. | NCT04949191 | Advanced Malign... | Pemigatinib Retifanlimab Pembrolizumab | 18 Years - 90 Years | Incyte Corporation | |
| A Clinical Study of MIL95 in Advanced Malignancies. | NCT04651348 | Advanced Malign... | Recombinant Hum... | 18 Years - | Beijing Mabworks Biotech Co., Ltd. | |
| Study of PWT33597 Mesylate in Subjects With Advanced Malignancies | NCT01407380 | Malignancies | PWT33597 mesyla... | 18 Years - | Pathway Therapeutics, Inc. | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. | NCT04831944 | Advanced Malign... | parsaclisib | 18 Years - 80 Years | Incyte Corporation | |
| Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies | NCT02326441 | Advance Maligna... | KX2-361 | 18 Years - | Athenex, Inc. | |
| Docetaxel and Sirolimus in Patients With Advanced Malignancies | NCT01054313 | Advanced Cancer | Docetaxel (Taxo... Sirolimus (Rapa... Prednisone | - | M.D. Anderson Cancer Center | |
| Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) | NCT01201694 | Advanced Cancer... | Surface-Control... Surface-Control... | 13 Years - | M.D. Anderson Cancer Center | |
| Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | NCT03474640 | Advanced Malign... | Toripalimab, Re... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| A Study of SHR-1501 in Patients With Advanced Tumors | NCT04025957 | Advanced Malign... | SHR-1501 | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | NCT02265510 | Solid Tumors Advanced Malign... Metastatic Canc... | INCB052793 gemcitabine nab-paclitaxel dexamethasone Carfilzomib bortezomib lenalidomide azacitidine INCB052793 pomalidomide INCB050465 INCB039110 | 18 Years - | Incyte Corporation | |
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT05359692 | Metastatic Head... Advanced Malign... Recurrent Head ... | INCAGN01876 retifanlimab | 18 Years - 99 Years | Incyte Corporation | |
| Study of PWT33597 Mesylate in Subjects With Advanced Malignancies | NCT01407380 | Malignancies | PWT33597 mesyla... | 18 Years - | Pathway Therapeutics, Inc. | |
| Maintenance Study on the Long Term Safety of XL999 | NCT00955084 | Advanced Malign... | XL999 | 18 Years - | Symphony Evolution, Inc. | |
| Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies. | NCT05024305 | Advanced Malign... | TWP-102 injecti... | 18 Years - 75 Years | Shandong TheraWisdom Biopharma Co., Ltd. | |
| Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer | NCT01266057 | Advanced Cancer... | Hydroxychloroqu... Sirolimus Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies | NCT00083525 | Advanced Malign... | WX-UK1 in combi... | 18 Years - | Heidelberg Pharma AG | |
| A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors | NCT04085185 | Advanced Malign... | IBI110 IBI110 IBI110+ Sintili... IBI110+ Sintili... | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies | NCT01015222 | Advanced Cancer | Dasatinib Bevacizumab Paclitaxel | - | M.D. Anderson Cancer Center | |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | NCT05061537 | Renal Cell Canc... Melanoma Non-Small-Cell ... Hepatocellular ... Bladder Cancer Sarcoma Head and Neck C... Colorectal Canc... Ovarian Cancer Squamous Cell C... | PF-07263689 Sasanlimab | 18 Years - | Pfizer | |
| Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | NCT03474640 | Advanced Malign... | Toripalimab, Re... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Process and Outcomes of Pain Management | NCT00028249 | Pain Neoplasm | - | National Institutes of Health Clinical Center (CC) | ||
| Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | NCT03407976 | Advanced Malign... Urothelial Carc... MSI-H or dMMR S... Gastric or Gast... | Apatinib Pembrolizumab | 18 Years - | University of Utah | |
| Process and Outcomes of Pain Management | NCT00028249 | Pain Neoplasm | - | National Institutes of Health Clinical Center (CC) | ||
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | NCT05891171 | Advanced Cancer Advanced Malign... Bladder Cancer Cervical Cancer Esophageal Canc... Gastric Cancer Gastroesophagea... Head and Neck S... Non-Small Cell ... Ovarian Cancer Renal Cell Carc... Triple Negative... | AB598 Zimberelimab Carboplatin Pemetrexed Fluorouracil Leucovorin Oxaliplatin | 18 Years - | Arcus Biosciences, Inc. | |
| Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies | NCT01339871 | Advanced Cancer | Pazopanib Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 1 Dose Escalation Study of IPI-493 | NCT00724425 | Advanced Malign... | IPI-493 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | NCT01625234 | Advanced Solid ... Non-small Cell ... | Phase I: X-396 ... Phase II: X-396... | 18 Years - | Xcovery Holdings, Inc. | |
| Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies | NCT00083525 | Advanced Malign... | WX-UK1 in combi... | 18 Years - | Heidelberg Pharma AG | |
| A Phase 1 Dose Escalation Study of IPI-493 | NCT00724425 | Advanced Malign... | IPI-493 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies. | NCT00426140 | Advanced Malign... Solid Tumors | Patupilone | 18 Years - | Novartis | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
